Did Oncotype DX® Recurrence Score Accurately Predict the Risk of Recurrence in Breast Cancer? A 10 Year Period Study in a Single Institution

The 21-gene Recurrence Score (RS) assay ( Oncotype DX ® ) predicts the risk of recurrence and benefit from chemotherapy in estrogen receptor (ER) positive, Her-2/ neu negative, node negative and, more recently, limited node-positive (≤3) breast cancer. The 21-gene RS is divided into low, intermediat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Open medicine journal 2015-07, Vol.2 (1), p.37-42
Hauptverfasser:	Torous, Vanda Farahmand, Apple, Sophia K
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!